Possible scenario
Narrow Oversight Review
45% Chance
Federal health agencies treat the findings as a biosafety and animal-welfare compliance problem rather than a reason to halt all high-containment research. Congress asks for records from NIH, NIAID, BARDA, and USAMRIID, but the near-term market impact stays confined to vaccine developers and research contractors.
Secondary impacts
- Healthcare -0.3%
- Business Services -0.2%
Tickers
- CRL-0.8%
- MRK-0.6%
- LH-0.4%
Portfolio impact
S&P 500-0.0%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.